ViAqua Therapeutics Ltd.

ViAqua Therapeutics Ltd. is an Israeli biotechnology startup focusing on aquaculture health enhancement. The company's primary mission is to provide effective and affordable health management solutions for the aquaculture industry. ViAqua's innovative oral delivery platform, co-developed with Skretting (a Nutreco company), is designed to deliver RNA to induce resistance to White Spot Shrimp Virus in shrimp-feed. This pioneering approach addresses the growing need for sustainable disease management in aquaculture. The company was founded in 2014 and operates within the biotechnology and healthcare industries. Its recent milestone includes securing an $8.25M Venture Round investment on 05 September 2023. This investment round saw participation from a consortium of notable investors, including S2G Ventures, Trendlines Group, Rabo Ventures, Agriline Ltd., I-Lab Angels, Circle Investments, and Nutreco. ViAqua Therapeutics' commitment to advancing aquaculture sustainability and its ability to attract significant investment from reputable firms underscore the market potential and confidence in its innovative approach. As the global demand for sustainable and efficient aquaculture continues to rise, ViAqua's technology and partnerships position it as a key player in addressing critical industry challenges and driving positive impact.